Journal article · 2021 · Open access
Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine
Drug Delivery and Translational Research, 11(4), 1309–1315 · Published 29 January 2021 · DOI 10.1007/s13346-021-00911-y
In brief
“Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine” is a 2021 journal article by Lara Scheherazade Milane and Mansoor M. Amiji, published in Drug Delivery and Translational Research. OpenAlex counts 135 citations as of 22 November 2026, which puts it in the top 1% of works published in 2021 by citations. It is open access: the full text is free to read at Drug Delivery and Translational Research.
- Citations
- 135
- Most cited in
- 2022 (40)
- Field-weighted impact
- 6.60
- References
- 15
- Authors
- 2
Abstract
One year after the first human case of SARS-CoV-2, two nanomedicine-based mRNA vaccines have been fast-tracked, developed, and have received emergency use authorization throughout the globe with more vaccine approvals on the heels of these first two. Several SARS-CoV-2 vaccine compositions use nanotechnology-enabled formulations. A silver lining of the COVID-19 pandemic is that the fast-tracked vaccine development for SARS-CoV-2 has advanced the clinical translation pathway for nanomedicine drug delivery systems. The laboratory science of lipid-based nanoparticles was ready and rose to the clinical challenge of rapid vaccine development. The successful development and fast tracking of SARS-CoV-2 nanomedicine vaccines has exciting implications for the future of nanotechnology-enabled drug and gene delivery; it demonstrates that nanomedicine is necessary and critical to the successful delivery of advanced molecular therapeutics such as nucleic acids, it is establishing the precedent of safety and the population effect of phase four clinical trials, and it is laying the foundation for the clinical translation of more complex, non-lipid nanomedicines. The development, fast-tracking, and approval of SARS-CoV-2 nanotechnology-based vaccines has transformed the seemingly daunting challenges for clinically translating nanomedicines into measurable hurdles that can be overcome. Due to the tremendous scientific achievements that have occurred in response to the COVID-19 pandemic, years, perhaps even decades, have been streamlined for certain translational nanomedicines.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Milane, L. S., & Amiji, M. M. (2021). Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Drug Delivery and Translational Research, 11(4), 1309–1315. https://doi.org/10.1007/s13346-021-00911-y
MLA 9
Milane, Lara Scheherazade, and Mansoor M. Amiji. “Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.” Drug Delivery and Translational Research, vol. 11, no. 4, 2021, pp. 1309–1315. https://doi.org/10.1007/s13346-021-00911-y.
Chicago
Milane, Lara Scheherazade and Mansoor M. Amiji. 2021. “Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.” Drug Delivery and Translational Research 11 (4): 1309–1315. https://doi.org/10.1007/s13346-021-00911-y.
Harvard
Milane, L. S. and Amiji, M. M. (2021) ‘Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine’, Drug Delivery and Translational Research, 11(4), pp. 1309–1315. doi:10.1007/s13346-021-00911-y.
IEEE
L. S. Milane and M. M. Amiji, “Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine,” Drug Delivery and Translational Research, vol. 11, no. 4, pp. 1309–1315, 2021, doi: 10.1007/s13346-021-00911-y.
BibTeX
@article{milane2021clinical,
title = {{Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine}},
author = {Milane, Lara Scheherazade and Amiji, Mansoor M.},
journal = {Drug Delivery and Translational Research},
year = {2021},
volume = {11},
number = {4},
pages = {1309--1315},
doi = {10.1007/s13346-021-00911-y},
url = {https://doi.org/10.1007/s13346-021-00911-y}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2021 | 29 | |
| 2022 | 40 | |
| 2023 | 17 | |
| 2024 | 22 | |
| 2025 | 13 | |
| 2026 | 14 |
Its field-weighted citation impact is 6.60: it has been cited 6.60 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- COVID-19 mRNA vaccine
- lipid nanoparticles
- nanomedicine
- clinical translation
- vaccine approval
- emergency use authorization
- COVID-19 pandemic
- nucleic acid delivery
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Milane, L. S., & Amiji, M. M. (2021). Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Drug Delivery and Translational Research, 11(4), 1309–1315. https://doi.org/10.1007/s13346-021-00911-y
How many times has this paper been cited?
135 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Drug Delivery and Translational Research: sign in and open the PDF from this page.
Who wrote this paper?
Lara Scheherazade Milane, Mansoor M. Amiji.
What is the DOI of this paper?
10.1007/s13346-021-00911-y, permanently at https://doi.org/10.1007/s13346-021-00911-y. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.